Pyridine Derivatives Induce Apoptosis in Leukemia Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are ineffective due to the disease's heterogeneity and poor understanding of leukemogenic mutations, leading to unsatisfactory clinical outcomes, with a need for novel therapeutic agents that target common characteristics of AML cells without harming normal tissues.
Innovation Solution
Development of disubstituted pyridine derivatives that induce apoptosis in cancer cells, specifically designed to target and kill leukemia cells by disrupting the balance between pro- and anti-oxidant forces, using compounds like dienaminone derivatives and their pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cytotoxic, targeted, and hematopoietic stem cell transplant therapy are used to treat AML, then treatment options are provided, but clinical outcomes remain unsatisfactory with poor survival rates
Solution Approach 1:
The patent modifies the chemical structure of pyridine derivatives by changing parameters such as substituent types (aryl, heteroaryl, alkyl groups) and their positions on the pyridine ring, thereby optimizing the compounds' cytotoxic activity and selectivity against AML cells while reducing harm to normal tissues
Solution Approach 2:
The patent creates composite molecular structures by combining pyridine core structures with various functional groups and substituents (e.g., carbonyl groups, amino groups, aromatic rings) to generate diversified compounds with enhanced biological activity and selective cytotoxicity
2Measurement precision
If therapy targets specific leukemogenic mutations, then treatment precision is improved, but the heterogeneity of AML makes it difficult to identify universal targets
Solution Approach 1:
The patent develops pyridine derivatives that target a broader characteristic common to all AML cells - the disrupted balance between pro- and anti-oxidant forces - rather than focusing on specific mutations, thereby creating a universal therapeutic approach that works across different AML subtypes and genetic profiles
Solution Approach 2:
The patent optimizes the chemical parameters of the pyridine derivatives (such as electron-withdrawing or electron-donating properties of substituents) to enhance their ability to disrupt the oxidant-antioxidant balance, making them effective across the heterogeneous population of AML cells
3Productivity
If cytotoxic therapy is used to kill cancer cells, then tumor burden is reduced, but normal tissues are also harmed
Solution Approach 1:
The patent introduces functional groups and substituents on the pyridine ring that confer selective cytotoxicity, allowing the compound to exert its harmful effect specifically on AML cells through their unique biochemical characteristics (disrupted oxidant-antioxidant balance) while sparing normal tissues
Solution Approach 2:
The patent exploits the fact that AML cells have an increased susceptibility to disruption of the balance between pro- and anti-oxidant forces as a vulnerability. The pyridine derivatives are designed to target this specific vulnerability, converting the cells' metabolic imbalance into a liability that enhances their susceptibility to cytotoxicity while normal cells, with their balanced oxidant-antioxidant systems, remain resistant
Data Source
AI summary
Methods of inducing apoptosis of cancer cells by contacting the cancer cells with a pyridine derivative are provided. Methods of treating a subject suffering from a hyperproliferative disease or complications thereof comprising the step of administering a therapeutically effective amount of a composition to the subject, wherein the composition comprises pyridine derivatives are provided.